pharmaphorum4 天
Dupixent scores a first in rare skin disease prurigo nodularis
Sanofi and Regeneron's Dupixent has become the first biologic drug to show activity in prurigo nodularis (PN), raising the hope of a new treatment option for the rare and highly debilitating skin ...
Business Wire1 个月
CHMP Recommends Approval of Galderma’s Nemolizumab for Moderate-to-Severe Atopic ...
This follows its approval for the treatment of adults with prurigo nodularis by the United States (U.S.) Food and Drug Administration (FDA) in August 2024. 14 Atopic dermatitis is a common ...
pharmaphorum3 年
Dupixent scores a first in rare skin disease prurigo nodularis
Sanofi and Regeneron's Dupixent has become the first biologic drug to show activity in prurigo nodularis (PN), raising the hope of a new treatment option for the rare and highly debilitating skin ...